PHASE-II STUDY OF VINBLASTINE-CCNU, TRIAZINATE, AND DACTINOMYCIN IN ADVANCED RENAL-CELL CANCER

Google Scholar
  • 1 January 1981
    • journal article
    • research article
    • Vol. 65  (7-8) , 711-713
Abstract
A total of 133 patients with advanced or metastatic adenocarcinoma of the kidney were stratified according to performance status and time from initial diagnosis to recurrence and were than randomized to 1 of 3 different drug treatment arms or the crossover secondary treatment. The study drugs (combination vinblastine-CCNU [1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea] and single-agent triazinate or dactinomycin) failed to provide any meaningful antitumor activity for these patients with advanced renal cell cancer.